Endogenous production of nitric oxide synthase inhibitors.
Numerous reports have indicated that the plasma concentration of endogenously produced inhibitors of nitric oxide synthase are elevated in human disease states. In this review we discuss recent advances in our understanding of the enzymes responsible for the synthesis of these inhibitors.
Anthony
Shelagh
S
Centre for Clinical Pharmacology, The British Heart Foundation Laboratories, University College London, UK.
Leiper
James
J
Vallance
Patrick
P
D001120:Arginine / Q000031:analogs & derivatives* / Q000097:blood / Q000378:metabolism / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000097:blood / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D007527:Isoenzymes / Q000235:genetics / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D011484:Protein-Arginine N-Methyltransferases / Q000235:genetics / Q000378:metabolism; D051437:Renal Insufficiency / Q000097:blood; D019323:omega-N-Methylarginine / Q000378:metabolism / Q000494:pharmacology
D004791:Enzyme Inhibitors; D007527:Isoenzymes; D019323:omega-N-Methylarginine; C018524:N,N-dimethylarginine; D001120:Arginine; D019001:Nitric Oxide Synthase; D011484:Protein-Arginine N-Methyltransferases